In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.
The ESC Guidelines on Pulmonary Hypertension on ESC TV

Watch the discussion between Miguel Angel Gomez Sanchez, Antonio Vaz Carneiro and Nazzareno Galié.

Watch the ESC tv interview
ESC Pocket Guidelines App

Get all the latest ESC Pocket Guidelines, plus interactive tools (algorithms, calculators, charts, scores...) in your pocket.

Guidelines Into Practice
Pulmonary Hypertension

Pulmonary Hypertension (Guidelines on Diagnosis and Treatment of)

ESC Clinical Practice Guidelines

Pulmonary Disease
Pulmonary Hypertension
Valvular Heart Diseases
Guidelines version available to download
Published in2015
Reference2015 Guidelines on Pulmonary Hypertension
Published in2015
ReferenceWeb Addenda
Published in2015
ReferenceCME Questions - Pulmonary Hypertension
Published in2015
ReferencePulmonary Hypertension Pocket Guidelines
  • PDA
  • Published in2015
    ReferenceESC Pocket Guidelines App
    Published in2015
    ReferenceKey Messages and Gaps in Evidence
    Published in
    Published in2009
    ReferenceEuropean Heart Journal (2009) 30, 2493–2537; doi:10.1093/eurheartj/ehp297
    Table of contents: Full Text (ESC Clinical Practice Guidelines)

    1. Preamble
    2. Introduction
    3. Definitions and classifications
    3.1 Definitions
    3.2. Classifications
    4. Epidemiology and genetics of pulmonary hypertension
    4.1 Epidemiology and risk factors
    4.2 Genetics
    5. Pulmonary hypertension diagnosis
    5.1 Diagnosis
    5.1.1 Clinical presentation
    5.1.2 Electrocardiogram
    5.1.3 Chest radiograph
    5.1.4 Pulmonary function tests and arterial blood gases
    5.1.5 Echocardiography
    5.1.6 Ventilation/perfusion lung scan
    5.1.7 High-resolution computed tomography, contrast enhanced computed tomography, and pulmonary angiography
    5.1.8 Cardiac magnetic resonance imaging
    5.1.9 Blood tests and immunology
    5.1.10 Abdominal ultrasound scan
    5.1.11 Right heart catheterization and vasoreactivity
    5.1.12 Genetic testing
    5.2 Diagnostic algorithm
    6. Pulmonary arterial hypertension (group 1)
    6.1 Clinical characteristics
    6.2 Evaluation of severity
    6.2.1 Clinical parameters, imaging and haemodynamics
    6.2.2 Exercise capacity
    6.2.3 Biochemical markers
    6.2.4 Comprehensive prognostic evaluation and riskassessment
    6.2.5 Definition of patient status
    6.2.6 Treatment goals and follow-up strategy
    6.3 Therapy
    6.3.1 General measures
    6.3.2 Supportive therapy
    6.3.3 Specific drug therapy
    6.3.4 Combination therapy
    6.3.5 Drug interactions
    6.3.6 Balloon atrial septostomy
    6.3.7 Advanced right ventricular failure
    6.3.8 Transplantation
    6.3.9 Treatment algorithm
    6.3.10 Diagnosis and treatment of pulmonary arterial hypertension complications  
    6.3.11 End of life care and ethical issues
    7. Specific pulmonary (arterial) hypertension subsets
    7.1 Paediatric pulmonary arterial hypertension
    7.1.1 Diagnosis
    7.1.2 Therapy
    7.2 Pulmonary arterial hypertension associated with adult congenital heart disease
    7.2.1 Diagnosis
    7.2.2 Therapy
    7.3 Pulmonary arterial hypertension associated with connective tissue disease
    7.3.1 Diagnosis
    7.3.2 Therapy
    7.4 Pulmonary arterial hypertension associated with portal hypertension
    7.4.1 Diagnosis
    7.4.2 Therapy
    7.5 Pulmonary arterial hypertension associated with human immunodeficiency virus infection
    7.5.1 Diagnosis
    7.5.2 Therapy
    7.6 Pulmonary veno-occlusive disease and pulmonary capillary haemangiomatosis
    7.6.1 Diagnosis
    7.6.2 Therapy
    8. Pulmonary hypertension due to left heart disease (group 2)
    8.1 Diagnosis
    8.2 Therapy
    9. Pulmonary hypertension due to lung diseases and/or hypoxia (group 3)
    9.1 Diagnosis
    9.2 Therapy
    10. Chronic thromboembolic pulmonary hypertension (group 4)
    10.1 Diagnosis
    10.2 Therapy
    10.2.1 Surgical
    10.2.2 Medical
    10.2.3 Interventional
    11. Pulmonary hypertension with unclear and/or multifactorial mechanisms (group 5)
    12. Definition of a pulmonary hypertension referral centre
    13. To do and not to do messages from the guidelines
    14. Appendix
    15. Web addenda
    16. References




    Back to top
    European Society
    of Cardiology

    Les Templiers
    2035 Route des Colles
    CS 80179 BIOT
    06903 Sophia Antipolis
    Cedex France